RECRUITING

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Conditions

Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia MDS CMML

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML. Eltrombopag is a Food and Drug Administration (FDA) approved drug for the treatment of severe aplastic anemia and low levels of platelets in patients with persistent or chronic immune thrombocytopenia (ITP) and chronic hepatitis C. Eltrombopag is considered investigational (experimental) in this study because the FDA has not approved its use in the treatment of low-risk MDS or CMML. Eltrombopag is a drug that helps stimulate the body's process of making more platelets (small components of blood that help with clotting) by interacting with specific parts of cells. This interaction starts a series of signals that encourage the growth and development of the cells that produce platelets. It was found that this drug could stop the growth of TET2 mutated cells.

Official Title

A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations

Quick Facts

Study Start:2025-06

Study Completion:2030-01-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06630221

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age ≥ 18 years at the time of signing the informed consent form. * Willing and able to adhere to the study visit schedule and other protocol requirements. * Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R \< 3.5) and \< 5% myeloblasts or CMML 0 (CMML-0, for cases with \< 2% blasts in PB and \< 5% blasts in bone marrow (BM)z,\[14\] with any one of the notable cytopenias as defined below: 1. Hgb \< 10 g/dL prior to enrollment 2. ANC \< 1.5×10\^9/L 3. Platelets \< 100×10\^9/L * Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs (i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy. * TET2 mutation performed at a frequency of at least \> 5%. * ECOG performance status of 0-2. * Adequate organ function, defined as: 1. Serum total bilirubin \< 2x ULN, unless the subject has Gilbert's syndrome. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis. In these cases, approval from the study PI is required. 2. Creatinine clearance greater than 30 mL/min based on the Cockroft-Gault glomerular filtration rate estimation. 3. Participants being enrolled on study on the basis of anemia, will only be eligible if folate, B12, serum iron, serum ferritin, total iron binding capacity, haptoglobin and peripheral smear within normal limits 4. Hepatitis panel negative for Hep B and Hep C infection 5. Negative for HIV infection * Women of childbearing potential (WOCBP) may participate provided they have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 h of starting treatment. * WOCBP and males with partners who are WOCBP must agree to abstain from sexual intercourse or use effective contraception (methods that result in \< 1% pregnancy rates) during eltrombopag therapy and for at least 7 days after the last eltrombopag dose. Males with partners who are WOCBP must agree to use a barrier method.	* High- and Very High-risk MDS (per IPSS-R) * CMML 1-2 * Prior HMA exposure * Platelet count \> 200×10\^9/uL or leukocytosis of at least 25×10⁹/L * Marrow fibrosis (any grade) * Results of bone marrow biopsy within 1 month of study entry (screening bone marrow biopsy) indicating high-risk MDS or CMML-2. * Elevated LFTs (aminotransferases and bilirubin) \> 2x ULN * Pre-existing cardiovascular disease (e.g., known coronary artery disease with percutaneous intervention or stroke within the last year) or arrhythmia (e.g., atrial fibrillation) associated with an increased risk of thromboembolic events, unless deemed acceptable by the enrolling treating physician. * History of arterial or venous thromboembolism, and on anticoagulation. * Severe hepatic impairment (Child-Pugh Class C) * Recent history of cancer (i.e., within the past 5 years) with \> 50% chance of cancer recurrence in the next 5 years * Current or prior history of hematologic malignancy * Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally. * Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.) * Positive direct Coombs test * Evidence of hypersplenism on physical exam * Pregnant or lactating (women)

Inclusion Criteria

Exclusion Criteria

* Age ≥ 18 years at the time of signing the informed consent form.
* Willing and able to adhere to the study visit schedule and other protocol requirements.
* Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R \< 3.5) and \< 5% myeloblasts or CMML 0 (CMML-0, for cases with \< 2% blasts in PB and \< 5% blasts in bone marrow (BM)z,\[14\] with any one of the notable cytopenias as defined below:
1. Hgb \< 10 g/dL prior to enrollment
2. ANC \< 1.5×10\^9/L
3. Platelets \< 100×10\^9/L
* Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs (i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy.
* TET2 mutation performed at a frequency of at least \> 5%.
* ECOG performance status of 0-2.
* Adequate organ function, defined as:
1. Serum total bilirubin \< 2x ULN, unless the subject has Gilbert's syndrome. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis. In these cases, approval from the study PI is required.
2. Creatinine clearance greater than 30 mL/min based on the Cockroft-Gault glomerular filtration rate estimation.
3. Participants being enrolled on study on the basis of anemia, will only be eligible if folate, B12, serum iron, serum ferritin, total iron binding capacity, haptoglobin and peripheral smear within normal limits
4. Hepatitis panel negative for Hep B and Hep C infection
5. Negative for HIV infection
* Women of childbearing potential (WOCBP) may participate provided they have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 h of starting treatment.
* WOCBP and males with partners who are WOCBP must agree to abstain from sexual intercourse or use effective contraception (methods that result in \< 1% pregnancy rates) during eltrombopag therapy and for at least 7 days after the last eltrombopag dose. Males with partners who are WOCBP must agree to use a barrier method.

* High- and Very High-risk MDS (per IPSS-R)
* CMML 1-2
* Prior HMA exposure
* Platelet count \> 200×10\^9/uL or leukocytosis of at least 25×10⁹/L
* Marrow fibrosis (any grade)
* Results of bone marrow biopsy within 1 month of study entry (screening bone marrow biopsy) indicating high-risk MDS or CMML-2.
* Elevated LFTs (aminotransferases and bilirubin) \> 2x ULN
* Pre-existing cardiovascular disease (e.g., known coronary artery disease with percutaneous intervention or stroke within the last year) or arrhythmia (e.g., atrial fibrillation) associated with an increased risk of thromboembolic events, unless deemed acceptable by the enrolling treating physician.
* History of arterial or venous thromboembolism, and on anticoagulation.
* Severe hepatic impairment (Child-Pugh Class C)
* Recent history of cancer (i.e., within the past 5 years) with \> 50% chance of cancer recurrence in the next 5 years
* Current or prior history of hematologic malignancy
* Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
* Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.)
* Positive direct Coombs test
* Evidence of hypersplenism on physical exam
* Pregnant or lactating (women)

Contacts and Locations

Study Contact

Abhay Singh, MD, MPH

CONTACT

1-866-223-8100

TaussigResearch@ccf.org

Principal Investigator

Abhay Singh, MD, MPH

PRINCIPAL_INVESTIGATOR

Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute

Study Locations (Sites)

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

Cleveland, Ohio, 44195

United States

Collaborators and Investigators

Sponsor: Abhay Singh, MD MPH

Abhay Singh, MD, MPH, PRINCIPAL_INVESTIGATOR, Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06

Study Completion Date2030-01-01

Study Record Updates

Study Start Date2025-06

Study Completion Date2030-01-01

Terms related to this study

Keywords Provided by Researchers

MDS
CMML

Additional Relevant MeSH Terms

Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia